BeiGene, Ltd. B1GN34.SA Stock
BeiGene, Ltd. Price Chart
BeiGene, Ltd. B1GN34.SA Financial and Trading Overview
| BeiGene, Ltd. stock price | 29.72 BRL |
| Previous Close | 39.63 BRL |
| Open | 0 BRL |
| Bid | 37.28 BRL x N/A |
| Ask | 39.36 BRL x N/A |
| Day's Range | 0 - 0 BRL |
| 52 Week Range | 0 - 53.25 BRL |
| Volume | 0 BRL |
| Avg. Volume | 163 BRL |
| Market Cap | 109.01B BRL |
| Beta (5Y Monthly) | 0.786619 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.31 BRL |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
B1GN34.SA Valuation Measures
| Enterprise Value | 799.53M BRL |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 70.00714 |
| Price/Book (mrq) | 0.9914808 |
| Enterprise Value/Revenue | 0.513 |
| Enterprise Value/EBITDA | -0.485 |
Trading Information
BeiGene, Ltd. Stock Price History
| Beta (5Y Monthly) | 0.786619 |
| 52-Week Change | 45.16% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 53.25 BRL |
| 52 Week Low | 0 BRL |
| 50-Day Moving Average | 48 BRL |
| 200-Day Moving Average | 40.71 BRL |
B1GN34.SA Share Statistics
| Avg. Volume (3 month) | 163 BRL |
| Avg. Daily Volume (10-Days) | 455 BRL |
| Shares Outstanding | 1.36B |
| Float | 57.08M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -123.11% |
| Operating Margin (ttm) | -110.36% |
| Gross Margin | -26.017% |
| EBITDA Margin | -105.88% |
Management Effectiveness
| Return on Assets (ttm) | -15.36% |
| Return on Equity (ttm) | -38.17% |
Income Statement
| Revenue (ttm) | 1.56B BRL |
| Revenue Per Share (ttm) | 15.04 BRL |
| Quarterly Revenue Growth (yoy) | 46.00% |
| Gross Profit (ttm) | -511062000 BRL |
| EBITDA | -1648758016 BRL |
| Net Income Avi to Common (ttm) | -1917048064 BRL |
| Diluted EPS (ttm) | -6.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.87B BRL |
| Total Cash Per Share (mrq) | 37.13 BRL |
| Total Debt (mrq) | 545.19M BRL |
| Total Debt/Equity (mrq) | 13.11 BRL |
| Current Ratio (mrq) | 3.75 |
| Book Value Per Share (mrq) | 39.91 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1823832960 BRL |
| Levered Free Cash Flow (ttm) | -1309241344 BRL |
Profile of BeiGene, Ltd.
| Country | Brazil |
| State | N/A |
| City | Grand Cayman |
| Address | 94 Solaris Avenue |
| ZIP | KY1-1108 |
| Phone | 345-949 4123 |
| Website | https://www.beigene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9400 |
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Q&A For BeiGene, Ltd. Stock
What is a current B1GN34.SA stock price?
BeiGene, Ltd. B1GN34.SA stock price today per share is 29.72 BRL.
How to purchase BeiGene, Ltd. stock?
You can buy B1GN34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BeiGene, Ltd.?
The stock symbol or ticker of BeiGene, Ltd. is B1GN34.SA.
Which industry does the BeiGene, Ltd. company belong to?
The BeiGene, Ltd. industry is Biotechnology.
How many shares does BeiGene, Ltd. have in circulation?
The max supply of BeiGene, Ltd. shares is 2.67B.
What is BeiGene, Ltd. Price to Earnings Ratio (PE Ratio)?
BeiGene, Ltd. PE Ratio is now.
What was BeiGene, Ltd. earnings per share over the trailing 12 months (TTM)?
BeiGene, Ltd. EPS is -3.31 BRL over the trailing 12 months.
Which sector does the BeiGene, Ltd. company belong to?
The BeiGene, Ltd. sector is Healthcare.